[Form 4] DENTSPLY SIRONA Inc. Insider Trading Activity

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MAZELSKY JONATHAN JAY reported acquisition or exercise transactions in this Form 4 filing.

DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky received a compensation grant of phantom stock units tied to the company’s common stock. On this Form 4, he was awarded 2,841.8303 shares of phantom stock at $10.56 per share, each economically equivalent to one share of common stock. Following this award, his total phantom stock balance is 20,021.6843 units, which will be settled in common stock after his service as a director ends. This is a non-cash, deferred compensation transaction rather than an open-market stock purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MAZELSKY JONATHAN JAY

Role null

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock (Directors' Deferred Compensation) DDC	2,841.83	$10.56	$30K

Holdings After Transaction: Phantom Stock (Directors' Deferred Compensation) DDC — 20,021.684 shares (Direct, null)

Footnotes (1)

Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. Comprised of phantom stock.

Key Figures

Phantom stock units granted: 2,841.8303 units Grant price per unit: $10.56 per unit Total phantom units after grant: 20,021.6843 units +2 more

5 metrics

Phantom stock units granted 2,841.8303 units Director deferred compensation grant on 2026-06-30

Grant price per unit $10.56 per unit Value per phantom stock share equivalent

Total phantom units after grant 20,021.6843 units Mazelsky’s phantom stock balance following transaction

Underlying common stock equivalence 2,841.8303 shares Each phantom unit equals one common share economically

Transaction code A (Grant, award, or other acquisition) Characterization of the Form 4 transaction

Key Terms

Phantom Stock, Directors' Deferred Compensation, economic equivalent, payable in common stock

4 terms

Phantom Stock financial

"Each share of phantom stock is the economic equivalent of one share of common stock."

A phantom stock is a form of compensation that gives employees or executives the benefits of stock ownership, such as the increase in stock value, without actually giving them real shares. It acts like a promise to pay the employee the equivalent value of company stock later, often as a bonus or incentive. This allows companies to motivate and reward staff without diluting ownership or transferring actual shares.

Directors' Deferred Compensation financial

"Phantom Stock (Directors' Deferred Compensation) DDC"

economic equivalent financial

"Each share of phantom stock is the economic equivalent of one share of common stock."

payable in common stock financial

"The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:36 PM Accepted by SEC EDGAR 07/01/2026 - 04:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAZELSKY JONATHAN JAY

(Last)

(First)

(Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE

NORTH CAROLINA

28277

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Phantom Stock (Directors' Deferred Compensation) DDC	⁽¹⁾	06/30/2026		A		2,841.8303⁽²⁾		⁽¹⁾	⁽¹⁾	Common Stock	2,841.8303	$10.56	20,021.6843	D

Explanation of Responses:

1. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director.

2. Comprised of phantom stock.

	/s/ Jessica Nielsen Causey, Attorney-in-Fact for Jonathan Jay Mazelsky	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did DENTSPLY SIRONA (XRAY) report for Jonathan Mazelsky?

DENTSPLY SIRONA reported that director Jonathan Jay Mazelsky received a grant of phantom stock units as deferred compensation. The award covers 2,841.8303 units, each tied economically to one share of common stock at $10.56 per unit.

How many phantom stock units did XRAY director Mazelsky receive in this filing?

Mazelsky received 2,841.8303 phantom stock units. Each unit is economically equivalent to one share of DENTSPLY SIRONA common stock, forming part of his directors’ deferred compensation rather than an open-market purchase.

What is the value per unit of the phantom stock granted to XRAY’s director?

Each phantom stock unit was valued at $10.56 per share. These units mirror the value of DENTSPLY SIRONA common stock and are payable in common shares after Mazelsky’s board service ends, according to the filing’s footnotes.

How many phantom stock units does XRAY director Mazelsky hold after this grant?

After this grant, Mazelsky holds a total of 20,021.6843 phantom stock units. These units will ultimately be settled in DENTSPLY SIRONA common shares following his termination of service as a director, under the plan’s terms.

Does the XRAY Form 4 show an open-market buy or sell by Jonathan Mazelsky?

No. The Form 4 reports a grant of phantom stock as deferred director compensation, coded as an acquisition (A). It does not reflect an open-market purchase or sale of DENTSPLY SIRONA common stock by Mazelsky.